<code id='681293899D'></code><style id='681293899D'></style>
    • <acronym id='681293899D'></acronym>
      <center id='681293899D'><center id='681293899D'><tfoot id='681293899D'></tfoot></center><abbr id='681293899D'><dir id='681293899D'><tfoot id='681293899D'></tfoot><noframes id='681293899D'>

    • <optgroup id='681293899D'><strike id='681293899D'><sup id='681293899D'></sup></strike><code id='681293899D'></code></optgroup>
        1. <b id='681293899D'><label id='681293899D'><select id='681293899D'><dt id='681293899D'><span id='681293899D'></span></dt></select></label></b><u id='681293899D'></u>
          <i id='681293899D'><strike id='681293899D'><tt id='681293899D'><pre id='681293899D'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:leisure time    Page View:33
          Dr. Laurie Glimcher, CEO of Dana Farber Cancer Institute, opens both arms while talking — coverage from STAT
          Laurie Glimcher, CEO of Dana Farber Cancer Institute, is the architect of the biggest shakeup in Boston health care in decades. David L. Ryan/Globe Staff

          Dr. Laurie Glimcher learned early on from her father, a prominent physician-researcher, that success in science was built on a basic principle: Big discoveries require big risks.

          The younger Glimcher took that advice to heart. In the late 1990s at her Harvard immunology lab, Glimcher and her postdoctoral student began a series of experiments that colleagues deemed “crazy.” But after a year of trial and error, the lab had a eureka moment when it found that white blood cells could be reprogrammed, a seminal discovery that led to new ways to treat cancer.

          advertisement

          “Most scientists do good work, but they don’t transform a scientific question,” said Glimcher. “I always felt the only way to do that is to think big and go after something that’s going to be really important.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Despite FDA approval for Lyfgenia, Bluebird faces stiff competition
          Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

          ChristineKao/STATTheFoodandDrugAdministration’sapprovalonFridayoftwogenetherapiesforsicklecelldiseas

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

          ThousandsofIsraelismarchtoJerusaleminprotestofplansbyPrimeMinisterBenjaminNetanyahu'sgovernmenttoove